U.S.-based startups secured significant venture capital funding last week, led by Science’s $400 million Series D in neurotechnology, underscoring continued investor appetite for frontier tech across sectors.

  • Science secures $400M Series D for brain-computer interfaces
  • Model ML raises $250M at $1.5B valuation for AI fintech platform
  • Multiple biotech startups close $100M+ funding rounds

What happened

Last week saw U.S. startups attract major venture capital financing, with ten companies raising $100 million or more. Leading the pack, Science, a brain-computer interface and neural engineering company based in Alameda, California, announced a $400 million Series D round, bringing its total financing to over $900 million. This signals strong confidence in neurotechnology's potential to revolutionize healthcare and human-machine interaction.

Beyond neurotech, notable rounds included Model ML, an AI platform serving financial and professional services, which raised $250 million in Series B funding at a $1.5 billion valuation. Several biotech startups such as Galvanize Therapeutics and Marrow Therapeutics also secured substantial funding of $130 million and $120 million respectively. Other sectors represented in the week’s largest rounds include space tech, critical metals production, and enterprise AI.

Why it matters

The sizeable capital influx into Science and other frontier technology startups underscores continued investor enthusiasm for sectors that blend advanced science with commercial potential. Neurotechnology, in particular, is garnering unprecedented funding, reflecting belief in its capability to transform medicine and human-computer symbiosis. Similarly, AI’s expanding presence in finance and enterprise sectors attracted major investments, highlighting the increasing integration of AI-driven solutions in traditional industries.

The biotech sector remains a hotbed for innovation, with new therapies targeting oncology, chronic disease, and blood disorders among the companies drawing top-dollar funding. This pattern indicates a robust pipeline of medical innovation backed by aggressive growth capital deployments. Meanwhile, startups in space infrastructure and sustainable critical materials production highlight the broad scope of emerging technologies underpinning future economic growth.

What to watch next

Investors and industry observers will be closely monitoring how Science leverages its newly raised capital to advance brain-computer interface technologies and secure regulatory milestones. The company’s progress will serve as a bellwether for neurotech’s broader commercial viability. Likewise, AI startups like Model ML are expected to demonstrate scalable enterprise applications that justify their high valuations amidst shifting market conditions.

In biotech, the upcoming clinical and regulatory developments from recently funded startups such as Galvanize Therapeutics and Marrow Therapeutics will be pivotal in validating their innovative approaches and attracting follow-on investment. Additionally, the space technology and critical metals sectors warrant attention as their growth trajectories may impact supply chains crucial to broader technology ecosystems.

Source assisted: This briefing began from a discovered source item from Crunchbase News. Open the original source.
How SignalDesk reports: feeds and outside sources are used for discovery. Public briefings are edited to add context, buyer relevance and attribution before they are published. Read the standards

Related briefings